Information on donor and conditioning for all children, and for children with and without verified FHL
| Variable . | All children (N = 187) . | Children with FHL (n = 134) . | Children without verified FHL (n = 53) . |
|---|---|---|---|
| Type of donor, n (% of entire group) | |||
| MRD | 44 (24) | 31 (23) | 13 (25) |
| MUD | 60 (32) | 45 (34) | 15 (28) |
| Haploidentical donor | 11 (6) | 7 (5) | 4 (8) |
| MMUD | 6 (3) | 3 (2) | 3 (6) |
| UCB | 53 (28) | 39 (29) | 14 (26) |
| Missing information on donor type | 13 (7) | 9 (7) | 4 (8) |
| Conditioning, n (% of entire group) | |||
| Busulfan-based | 99 (53) | 69 (52) | 30 (57) |
| Fludarabine-based | 39 (21) | 26 (19) | 13 (25) |
| Treosulfan-based | 20 (11) | 18 (13) | 2 (4) |
| Missing information on conditioning | 29 (16) | 21 (16) | 8 (15) |
| Variable . | All children (N = 187) . | Children with FHL (n = 134) . | Children without verified FHL (n = 53) . |
|---|---|---|---|
| Type of donor, n (% of entire group) | |||
| MRD | 44 (24) | 31 (23) | 13 (25) |
| MUD | 60 (32) | 45 (34) | 15 (28) |
| Haploidentical donor | 11 (6) | 7 (5) | 4 (8) |
| MMUD | 6 (3) | 3 (2) | 3 (6) |
| UCB | 53 (28) | 39 (29) | 14 (26) |
| Missing information on donor type | 13 (7) | 9 (7) | 4 (8) |
| Conditioning, n (% of entire group) | |||
| Busulfan-based | 99 (53) | 69 (52) | 30 (57) |
| Fludarabine-based | 39 (21) | 26 (19) | 13 (25) |
| Treosulfan-based | 20 (11) | 18 (13) | 2 (4) |
| Missing information on conditioning | 29 (16) | 21 (16) | 8 (15) |
Donor typing was performed on HLA class I (A, B) and class II (DR), as stated in the protocol.12